Detalles de la búsqueda
1.
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Blood
; 137(16): 2231-2242, 2021 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33512413
2.
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
N Engl J Med
; 379(9): 811-822, 2018 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-30157389
3.
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
N Engl J Med
; 377(9): 809-818, 2017 08 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-28691557
4.
Determining meaningful health-related quality-of-life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL).
Haemophilia
; 26(6): 1019-1030, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33084166
5.
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.
Pediatr Blood Cancer
; 67(10): e28474, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32776489
6.
Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting.
Haemophilia
; 25(2): 213-220, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30724422
7.
Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).
Haemophilia
; 25(3): 382-391, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31016855
8.
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
Haemophilia
; 25(1): 33-44, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30427582
9.
Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study.
Haemophilia
; 24(6): 921-929, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30295389
10.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
N Engl J Med
; 370(12): 1101-10, 2014 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-24401022
11.
Comparison of design strategies for a three-arm clinical trial with time-to-event endpoint: Power, time-to-analysis, and operational aspects.
Biom J
; 58(6): 1295-1310, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27346746
12.
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.
Blood
; 119(22): 5126-32, 2012 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-22431570
13.
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.
Res Pract Thromb Haemost
; 6(6): e12782, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36171959
14.
Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
J Thromb Haemost
; 17(9): 1470-1477, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31124272
15.
Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
Curr Med Res Opin
; 35(12): 2079-2087, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31355677
16.
Reply: RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087.
Curr Med Res Opin
; 36(7): 1129-1130, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32180474
17.
Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.
J Clin Oncol
; 31(23): 2912-9, 2013 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-23835718
Resultados
1 -
17
de 17
1
Próxima >
>>